601607 上海医药
已收盘 03-20 15:00:00
资讯
新帖
简况
上海医药(601607.SH)：注射用头孢唑林钠通过一致性评价
智通财经 · 03-17
上海医药(601607.SH)：注射用头孢唑林钠通过一致性评价
上海医药：2025年公司与多家药企达成战略合作
证券日报 · 03-02
上海医药：2025年公司与多家药企达成战略合作
每周股票复盘：上海医药（601607）利伐沙班片获新加坡注册证
证券之星 · 03-01
每周股票复盘：上海医药（601607）利伐沙班片获新加坡注册证
上海医药(02607)：普瑞巴林胶囊获得菲律宾药品注册证书
智通财经 · 02-27
上海医药(02607)：普瑞巴林胶囊获得菲律宾药品注册证书
上海医药(601607.SH)：利伐沙班片获得新加坡药品注册证书
智通财经 · 02-24
上海医药(601607.SH)：利伐沙班片获得新加坡药品注册证书
新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎
21世纪经济报道 · 02-12
新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎
上海医药(02607)：赵勇获选举为职工董事
智通财经 · 02-11
上海医药(02607)：赵勇获选举为职工董事
上海医药最新公告：下属公司盐酸坦索罗辛原料药上市申请获得批准
证券之星 · 02-11
上海医药最新公告：下属公司盐酸坦索罗辛原料药上市申请获得批准
上海医药原研1.1类创新药苹果酸司妥吉仑片在浦东开出首张处方
人民财讯 · 02-10
上海医药原研1.1类创新药苹果酸司妥吉仑片在浦东开出首张处方
每周股票复盘：上海医药（601607）拟挂牌转让施贵宝30%股权
证券之星 · 02-08
每周股票复盘：上海医药（601607）拟挂牌转让施贵宝30%股权
上海医药最新公告：拟不低于10.23亿元公开挂牌转让中美施贵宝30%股权
证券之星 · 02-04
上海医药最新公告：拟不低于10.23亿元公开挂牌转让中美施贵宝30%股权
上海医药(601607.SH)：西格列汀二甲双胍缓释片获得批准生产
智通财经 · 02-04
上海医药(601607.SH)：西格列汀二甲双胍缓释片获得批准生产
上海医药：公司推动新零售一体化战略
证券日报 · 02-02
上海医药：公司推动新零售一体化战略
每周股票复盘：上海医药（601607）七味防己黄芪颗粒获临床试验批准
证券之星 · 02-01
每周股票复盘：上海医药（601607）七味防己黄芪颗粒获临床试验批准
AI重塑医药生产力，为何超六成医药企业拥抱钉钉？
上观新闻 · 01-30
AI重塑医药生产力，为何超六成医药企业拥抱钉钉？
上海医药：关于公司控股股东及一致行动人的增持计划，目前正在有序实施中
证券日报 · 01-29
上海医药：关于公司控股股东及一致行动人的增持计划，目前正在有序实施中
上海医药(02607)：七味防己黄芪颗粒获得临床试验批准通知书
智通财经 · 01-29
上海医药(02607)：七味防己黄芪颗粒获得临床试验批准通知书
每周股票复盘：上海医药（601607）B023细胞注射液获临床试验批准
证券之星 · 01-25
每周股票复盘：上海医药（601607）B023细胞注射液获临床试验批准
上海医药最新公告：马来酸阿伐曲泊帕片获得批准生产
证券之星 · 01-23
上海医药最新公告：马来酸阿伐曲泊帕片获得批准生产
上海医药：普瑞巴林胶囊获得药品注册证书
南方财经网 · 01-23
上海医药：普瑞巴林胶囊获得药品注册证书
加载更多
公司概况
公司名称：
上海医药集团股份有限公司
所属行业：
零售业
上市日期：
1994-03-24
主营业务：
上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是硫酸羟氯喹片、多糖铁复合物胶囊、注射用乌司他丁、胃复春胶囊、双歧杆菌三联活菌制剂。报告期内，公司再度入选《财富》世界500强和全球最具价值医药品牌榜25强，排名分别提升至第407位和第19位。
发行价格：
4.50
{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":16.89,"timestamp":1773990000000,"preClose":17.08,"halted":0,"volume":12605600,"delay":0,"changeRate":-0.0111,"floatShares":2789000000,"shares":3708000000,"eps":1.5224,"marketStatus":"已收盘","change":-0.19,"latestTime":"03-20 15:00:00","open":17.08,"high":17.14,"low":16.89,"amount":214000000,"amplitude":0.0146,"askPrice":16.89,"askSize":740,"bidPrice":16.88,"bidSize":1786,"shortable":0,"etf":0,"ttmEps":1.5224,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774229400000},"marketStatusCode":5,"adr":0,"adjPreClose":17.08,"symbolType":"stock","openAndCloseTimeList":[[1773970200000,1773977400000],[1773982800000,1773990000000]],"highLimit":18.79,"lowLimit":15.37,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3708361809,"isCdr":false,"pbRate":0.83,"roa":"--","peRate":11.094325,"roe":"6.96%","epsLYR":1.23,"committee":0.186294,"marketValue":62634000000,"turnoverRate":0.0045,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-03-23。","hkstockBrief":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.36,"timestamp":1773994128005,"preClose":11.42,"halted":0,"volume":2009200,"delay":0,"premium":"-40.72"},"floatMarketCap":47110000000},"requestUrl":"/m/hq/s/601607","defaultTab":"news","newsList":[{"id":"2620441803","title":"上海医药(601607.SH)：注射用头孢唑林钠通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2620441803","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620441803?lang=zh_cn&edition=full","pubTime":"2026-03-17 15:37","pubTimestamp":1773733056,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)公告，公司下属上海上药新亚药业有限公司(简称“上药新亚”)的注射用头孢唑林钠收到国家药品监督管理局颁发的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。注射用头孢唑林钠适用于治疗敏感细菌所致的呼吸道感染、尿路感染、皮肤和软组织感染、骨和关节感染、败血症、感染性心内膜炎、肝胆系统感染、生殖系统感染和围手术期预防感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601607","BK0196","BK0184","BK0097","BK0187","BK0020","BK0012","BK0099","BK0175","02607","BK1197","BK0209","BK0188","BK0183","BK0028"],"gpt_icon":0},{"id":"2616334712","title":"上海医药：2025年公司与多家药企达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2616334712","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616334712?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:35","pubTimestamp":1772454923,"startTime":"0","endTime":"0","summary":"证券日报网3月2日讯，上海医药在接受调研者提问时表示，公司早年依托既有渠道网络优势，提前布局为制药企业提供合规的合约销售服务，帮助制药企业以更具成本效益的方式拓展市场，加速市场覆盖。凭借严谨合规的管理体系和专业的业务能力，公司已形成品牌美誉度。2025年，公司与多家药企达成战略合作，实现了服务规模与服务能级的双提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603023658779879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","BK0020","BK0099","BK0188","BK1197","BK0183","BK0097","BK0184","BK0028","02607","BK0187","BK0196","601607","BK0209","BK0175"],"gpt_icon":0},{"id":"2616454408","title":"每周股票复盘：上海医药（601607）利伐沙班片获新加坡注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2616454408","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616454408?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:59","pubTimestamp":1772305147,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，上海医药报收于17.2元，较上周的17.16元上涨0.23%。本周，上海医药2月25日盘中最高价报17.34元。公司公告汇总上海医药集团股份有限公司下属常州制药厂有限公司生产的利伐沙班片获得新加坡食品药品监督管理局颁发的药品注册证书，具备在新加坡上市销售资格。此前该药品已获美国FDA批准及马来西亚注册证书。截至公告日，公司在东南亚市场相关研发费用约219万元。目前菲律宾有19家销售商，2024年该药品市场销售额为1,337万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0188","BK0187","BK0028","02607","601607","BK0097","BK0184","BK0196","BK1197","BK0020","BK0175","BK0012","BK0183","BK0099"],"gpt_icon":0},{"id":"2614838513","title":"上海医药(02607)：普瑞巴林胶囊获得菲律宾药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2614838513","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614838513?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:39","pubTimestamp":1772181596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，近日，公司下属常州制药厂有限公司生产的普瑞巴林胶囊收到菲律宾食品药品监督管理局颁发的药品注册证书，该药品获得批准上市。普瑞巴林胶囊主要用于治疗带状疱疹后神经痛、糖尿病外周神经痛、纤维肌痛和脊髓损伤引起的神经性疼痛以及癫痫的辅助治疗。 本次普瑞巴林胶囊3个规格(50mg、75mg、150mg)获得菲律宾食品药品监督管理局的药品注册批文，标志着公司具备了在菲律宾市场销售该药品的资格，对公司拓展海外市场带来积极影响，并积累了宝贵的经验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","BK0183","BK0028","BK0188","BK0012","BK0209","BK1197","BK0097","BK0020","BK0184","601607","BK0187","BK0175","BK0099","BK0196"],"gpt_icon":0},{"id":"2613798673","title":"上海医药(601607.SH)：利伐沙班片获得新加坡药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2613798673","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613798673?lang=zh_cn&edition=full","pubTime":"2026-02-24 15:44","pubTimestamp":1771919082,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属常州制药厂有限公司(以下简称“常州制药厂”)生产的利伐沙班片(以下简称“该药品”)收到新加坡食品药品监督管理局(HSA)颁发的药品注册证书，该药品获得批准上市。本次利伐沙班片3个规格(10mg、15mg、20mg)获得新加坡食品药品监督管理局的药品注册批文，标志着该药品已具备在新加坡上市销售的资格，对公司拓展海外市场带来积极影响，并积累宝贵的经验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601607","BK0196","BK0184","BK0097","BK0187","BK0020","BK0012","BK0099","BK0175","02607","BK1197","BK0209","BK0188","BK0183","BK0028"],"gpt_icon":0},{"id":"2610960339","title":"新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2610960339","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610960339?lang=zh_cn&edition=full","pubTime":"2026-02-12 07:27","pubTimestamp":1770852424,"startTime":"0","endTime":"0","summary":"这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！政策动向国家卫健委等11部门联合印发《国家基本药物目录管理办法》2月11日，国家卫生健康委等联合印发《国家基本药物目录管理办法》。与原有的文件相比，《国家基本药物目录管理办法》主要修订六个方面：一是增加法律政策依据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602123648366353.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602123648366353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1580142542.USD","LU1781817850.SGD","301075","BK0077","BK0099","LU2580892862.HKD","LU1328615791.USD","LU1997245177.USD","600276","LU1064131003.USD","LU0405327494.USD","BK0097","300683","BK0070","LU2289578879.USD","BK0183","LU2097828631.EUR","BK0060","BK0028","LU2097828557.USD","LU0405327148.USD","LU1064130708.USD","LU2148510915.USD","LU2580892789.USD","LU1969619763.USD","BK0175","BK0188","LU2097828714.EUR","BK0046","BK0012","601607","300142","BK0209","BK0239","LU1255011170.USD","LU1820825898.SGD","BK0184","LU2097828474.EUR","LU1997245094.SGD","LU1997244956.HKD","LU2328871848.SGD","BK0187","BK0020","LU2097828805.USD","LU2495084118.USD","LU2488822045.USD","BK0196","LU1146622755.USD","LU1655091616.SGD"],"gpt_icon":0},{"id":"2610401938","title":"上海医药(02607)：赵勇获选举为职工董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2610401938","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610401938?lang=zh_cn&edition=full","pubTime":"2026-02-11 17:57","pubTimestamp":1770803826,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，于2026年2月11日召开的第三届职工代表大会第二次联席会议上，赵勇先生(赵先生)获选举为本公司第八届董事会职工董事，赵先生与经本公司股东会选举产生的董事共同组成本公司第八届董事会，任期自本公司职工代表大会选举之日起至第八届董事会任期届满之日止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404232.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","BK0028","BK0184","BK0099","BK0175","BK0187","BK0020","BK0209","601607","BK0012","BK1197","BK0196","BK0183","BK0188","BK0097"],"gpt_icon":0},{"id":"2610980551","title":"上海医药最新公告：下属公司盐酸坦索罗辛原料药上市申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2610980551","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610980551?lang=zh_cn&edition=full","pubTime":"2026-02-11 17:19","pubTimestamp":1770801585,"startTime":"0","endTime":"0","summary":"上海医药公告称，下属上药康丽（常州）药业有限公司收到国家药品监督管理局颁发的关于盐酸坦索罗辛原料药的《化学原料药上市申请批准通知书》。截至公告日，公司针对该药物已投入研发费用约人民币150万元。中国境内盐酸坦索罗辛原料药的主要生产厂家包括云鹏医药股份有限公司等。IQVIA数据库显示，2024年中国大陆医院采购盐酸坦索罗辛制剂金额为人民币41,382.75万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100027225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0012","601607","BK0175","BK0196","BK0209","BK0184","02607","BK0183","BK0028","BK0099","BK1197","BK0020","BK0187","BK0097"],"gpt_icon":0},{"id":"2610645934","title":"上海医药原研1.1类创新药苹果酸司妥吉仑片在浦东开出首张处方","url":"https://stock-news.laohu8.com/highlight/detail?id=2610645934","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610645934?lang=zh_cn&edition=full","pubTime":"2026-02-10 18:05","pubTimestamp":1770717948,"startTime":"0","endTime":"0","summary":"人民财讯2月10日电，2月10日，我国1.1类创新药——苹果酸司妥吉仑片（商品名“信妥安”），在上海市浦东新区公利医院开出首张处方。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602103646780111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","BK0187","BK0020","02607","BK0183","BK0028","159992","BK0012","BK0175","06978","BK0184","BK0099","601607","BK0097","BK1197","BK0209","BK1161","BK0188","BK1574"],"gpt_icon":0},{"id":"2609269245","title":"每周股票复盘：上海医药（601607）拟挂牌转让施贵宝30%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2609269245","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609269245?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:59","pubTimestamp":1770490748,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，上海医药报收于17.26元，较上周的17.3元下跌0.23%。本周，上海医药2月6日盘中最高价报17.38元。公司公告汇总上海医药集团股份有限公司于2026年2月4日召开第八届董事会第二十八次会议，审议通过《关于拟公开挂牌转让中美上海施贵宝制药有限公司30%股权的议案》。上海医药下属常州制药厂有限公司的西格列汀二甲双胍缓释片获得国家药品监督管理局批准生产，取得药品注册证书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800001037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0188","BK0184","02607","BK0099","BK0187","BK0196","BK0175","601607","BK0209","BK1197","BK0020","BK0097","BK0028","BK0012"],"gpt_icon":0},{"id":"2608009354","title":"上海医药最新公告：拟不低于10.23亿元公开挂牌转让中美施贵宝30%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2608009354","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608009354?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:35","pubTimestamp":1770197749,"startTime":"0","endTime":"0","summary":"上海医药(601607.SH)公告称，公司拟通过产权交易所以公开挂牌方式转让所持中美施贵宝30%股权，挂牌转让价格不低于10.23亿元，最终转让价格以公开挂牌成交结果为准。该交易不构成关联交易和重大资产重组，已在董事会审议通过，无需提交股东会。交易对方和最终交易价格尚未确定，存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400030085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0012","BK0196","BK1197","BK0175","BK0099","BK0187","601607","BK0028","BK0209","02607","BK0184","BK0020","BK0188","BK0097"],"gpt_icon":0},{"id":"2608935442","title":"上海医药(601607.SH)：西格列汀二甲双胍缓释片获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2608935442","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608935442?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:34","pubTimestamp":1770197682,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属常州制药厂有限公司(简称“常州制药厂”)的西格列汀二甲双胍缓释片收到国家药品监督管理局颁发的《药品注册证书》(证书编号：2026S00307)，该药品获得批准生产。西格列汀二甲双胍缓释片适用于正在接受西格列汀和二甲双胍缓释片联合治疗的成人2型糖尿病患者。该药品最早由Merck Sharp&Dohme公司开发，于2012年在美国上市。2024年6月常州制药厂就该药品向国家药监局提出注册上市申请，并获受理。截至本公告日，公司针对该药品已投入研发费用约人民币849万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0099","BK0209","BK0012","BK0028","BK0184","BK1197","BK0097","BK0196","BK0175","BK0020","02607","BK0188","BK0187","601607"],"gpt_icon":0},{"id":"2608864794","title":"上海医药：公司推动新零售一体化战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2608864794","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608864794?lang=zh_cn&edition=full","pubTime":"2026-02-02 21:37","pubTimestamp":1770039434,"startTime":"0","endTime":"0","summary":"证券日报网2月2日讯，上海医药在接受调研者提问时表示，公司推动新零售一体化战略，依托批零一体优势，加快院边药房、专业药房、线上平台的布局，旗下上药云健康作为处方药新零售“互联网+”平台，已成为创新药首发的重要渠道。同时，公司正在打造“商业保险+专业药房”的新业态，依托镁信健康商业保险创新先发优势，支持商业保险多元支付体系的建设。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638987098.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0099","BK0209","BK0012","BK0184","BK0187","601607","BK1197","BK0188","02607","BK0196","BK0175","BK0183","BK0020","BK0028","BK0097"],"gpt_icon":0},{"id":"2608778750","title":"每周股票复盘：上海医药（601607）七味防己黄芪颗粒获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2608778750","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608778750?lang=zh_cn&edition=full","pubTime":"2026-02-01 02:20","pubTimestamp":1769883621,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，上海医药报收于17.3元，较上周的17.48元下跌1.03%。本周关注点公司公告汇总：七味防己黄芪颗粒获临床试验批准，用于慢性心力衰竭。公司公告汇总上海医药集团股份有限公司下属正大青春宝药业有限公司研发的七味防己黄芪颗粒收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意该药品开展用于慢性心力衰竭的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0184","BK1197","BK0188","BK0028","BK0020","601607","BK0183","02607","BK0097","BK0187","BK0099","BK0012","BK0175","BK0209"],"gpt_icon":0},{"id":"2607025472","title":"AI重塑医药生产力，为何超六成医药企业拥抱钉钉？","url":"https://stock-news.laohu8.com/highlight/detail?id=2607025472","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607025472?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:43","pubTimestamp":1769737380,"startTime":"0","endTime":"0","summary":"以“AI重塑医药生产力”为主题的2026医药钉峰会日前在沪召开，共探人工智能技术如何驱动赋能医药行业。AI自动完成数据抓取、分析与预警，让人人皆可成为开发者，大幅提升了业务响应的敏捷性。此外，AI正成为药企全球化协同的基石。AI不再是遥远的技术概念，而是已经成为医药行业提质、增效、创新的核心驱动要素。随着AI技术产品持续完善、行业生态日益繁荣，一场以人工智能为核心的医药生产力革命，正从蓝图加速照进现实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130095032a466dcda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130095032a466dcda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014674.SGD","LU2097828631.EUR","601607","LU0348825331.USD","LU0348805143.USD","LU0831103253.SGD","LU1769817096.USD","LU0117841782.USD","SG9999002562.SGD","SG9999006514.SGD","LU0823413660.USD","LU0540923850.HKD","LU1328277881.USD","LU1568876251.USD","LU0456827905.SGD","BK1610","HK0000306685.HKD","LU0821914370.USD","02607","LU0873338254.USD","LU1504937902.USD","LU0979878070.USD","LU0823039010.USD","LU0348788117.USD","LU0531970944.HKD","HK0000165453.HKD","LU0196878994.USD","LU0348735423.USD","LU0898667661.SGD","LU1303224171.USD","LU0502904849.HKD","LU2087589342.USD","000538","IE00BZ08YS42.EUR","LU0359202008.SGD","LU0043850808.USD","LU1211504680.USD","BK1584","BK1608","LU1880383440.USD","LU0254981946.USD","LU1044875133.USD","LU1969619763.USD","SG9999006597.SGD","BK1591","LU1048596156.SGD","LU1655091459.SGD","LU0143863198.USD","LU0516422366.SGD","LU1794554557.SGD","LU0737861699.HKD","LU1242518857.USD","LU0886674414.USD","LU1719994722.HKD","SHPMY","BK1249","LU0640798160.USD","LU0823426308.USD","600276","LU1224709979.USD","LU2125910849.SGD","LU0823413587.USD","LU0348783233.USD","LU0164872284.USD","HBBD.SI","LU0169518387.USD","IE00BMPRXN33.USD","LU0214875030.USD","LU0791590937.USD","LU1770034418.SGD","LU2097828557.USD","LU0244354667.USD","LU0823040885.USD","LU0762542818.HKD","LU0293314216.USD","LU0593848301.USD","LU1807302812.USD","LU0608807433.USD","LU0210526637.USD","SG9999002828.SGD","SG9999001093.SGD","LU1115378108.SGD","LU0791591158.USD","LU0823426480.USD","LU1808992512.USD","LU0561508036.HKD","LU0577902298.EUR","LU0871576103.HKD","LU0784639295.USD","BK1517","LU1316542783.SGD","BK1618","LU0048388663.USD","IE0008368304.USD","LU0259732245.USD","LU1282651048.USD","LU1960683339.HKD","IE0003895053.USD","LU0143863784.USD","LU0117844026.USD","LU0541502299.USD","LU0449515922.USD","IE00BZ08YR35.GBP","LU0307460666.USD","SG9999000327.SGD","LU0499858602.USD","LU0327786744.USD","LU0128522744.USD","LU0052750758.USD","LU0608807946.USD","LU0417516902.SGD","SG9999000459.SGD","LU1961090484.USD","02157","LU0456846285.SGD","LU0455707207.USD","01801","LU1481107354.HKD","LU0675040207.SGD","LU0823038988.USD","LU0039217434.USD","LU0642271901.SGD","LU1323998911.USD","LU0326950275.SGD","LU0061477393.USD","LU0054237671.USD","LU0149721374.USD","BABA","LU0630378429.USD","LU1548497426.USD","BK1515","LU0890818403.SGD","LU1720050803.USD","LU0287142896.SGD","LU0630378692.HKD","LU0823397103.USD","LU2125910500.SGD","IE00B0JY6N72.USD","LU2242644610.SGD","LU0348827113.USD","LU0370786039.SGD","LU0084288322.USD","LU1810669033.SGD","LU0072462343.USD","LU2476274720.SGD","LU0348783662.USD","LU1251922891.USD","LU0862451753.SGD","LU0572940350.SGD","ALBmain","LU0762541174.USD","LU0589944569.HKD","LU0651946864.USD","LU0264606111.USD","LU1328615791.USD","LU2152927971.USD","LU0140636845.USD","LU0106252389.USD","LU0051755006.USD","LU0831093199.SGD","LU0210527791.USD","LU0229945570.USD","LU2476274308.USD","LU0463099449.HKD","IE0032431581.USD","IE00BZ08YT58.USD","LU0577902454.USD","LU0651947912.USD","LU1282651121.HKD","LU0029875118.USD","LU1224444064.USD","LU0605514214.HKD","LU0228659784.USD","LU0261950983.USD","LU1880398554.USD","LU1770036033.HKD","09988","BK1588","LU0228367735.SGD","LU0449509016.USD","LU2045819591.USD","LU1769817179.HKD","LU0329678170.USD","LU1282649141.HKD","LU0320764599.SGD","LU2097828805.USD","LU0231483743.USD","LU0164865239.USD","HK0000320223.HKD","LU0541501648.USD","LU0348784397.USD","LU0096374516.USD","SG9999004220.SGD","LU0048597586.USD","LU0047713382.USD","LU2449936058.SGD","LU0106259558.USD","LU0588545904.SGD","LU0499858438.USD","LU0856984785.SGD","LU0477156797.USD","LU0132412106.USD","SG9999001903.USD","IE0034224299.USD","LU0819123356.HKD","LU2293587155.HKD","LU0531971595.HKD","LU1044874839.SGD","LU1813983027.USD","LU1366334651.USD","IE00B5MMRT66.SGD","603127","LU0384037296.USD","LU0011963245.USD","LU0165289439.USD","BK1589","LU1201861165.SGD","LU0672654166.SGD","LU0431992006.USD","LU0516422440.USD","LU2039709279.SGD","LU0607220059.USD","LU1282649810.SGD","LU1880398471.USD","LU0708995153.HKD","LU1993786604.SGD","LU0417516738.SGD","LU0648000940.SGD","LU1688375341.USD","LU2399975544.HKD","LU0577902538.SGD","SGXZ90724238.SGD","LU0164880469.USD","LU2257852520.SGD","LU2778985437.USD","LU0329678337.USD","LU1642822792.SGD","LU1880383366.USD","LU0868486357.SGD","LU1720051108.HKD","LU0737861772.HKD","BK1142","BK1583","LU0441854154.USD","LU0611395673.USD","LU0328353924.USD","LU0823397285.USD","LU0048580855.USD","LU0315178854.USD","LU0862451837.USD","LU0708995583.HKD","LU0106959298.USD","LU2097829019.USD","LU0828237940.HKD","LU0823041008.USD","LU1188198961.HKD","HK0000306701.USD","LU0417516571.SGD","LU0488056044.USD","LU1051768304.USD","LU0359201612.USD","LU0588545730.USD","LU2328871848.SGD","LU0828237510.HKD","LU2357305700.SGD","LU1023057109.AUD","LU0315179316.USD","BK1575","LU0572944931.SGD","LU0577902611.USD","LU0235996351.USD","LU0127658192.USD","LU1366334578.USD","LU0762540952.USD","LU0516423091.SGD","BK1574","LU0594300179.USD","LU0594300419.USD","LU2097828714.EUR","LU0543330566.HKD","LU0516423174.USD","LU0577902371.SGD","LU0634319403.HKD","LU0181495838.USD","LU0197773673.USD","LU1956131251.USD","LU0130103400.USD","LU1981816686.USD","LU0543330483.HKD","LU0211977185.USD","LU1868837565.USD","IE00BPRC5H50.USD","LU0029874905.USD","LU1282649067.USD","LU0588546209.SGD","LU1868838027.USD","IE00BMPRXR70.SGD","LU0173614495.USD","LU0049853897.USD","LU1515016050.SGD","06127","IE00B0169N27.USD","LU0345776255.USD","LU0149534421.HKD","SG9999002463.SGD","LU1048588211.SGD","BK1586","LU1048484197.HKD","LU0650527681.SGD","SG9999001689.USD","LU0251144936.SGD","LU1439103000.SGD","LU1196710864.SGD","01276","LU1568876335.HKD","BK1161","LU0469268626.HKD","BK1521","LU0261947096.USD","LU0865486749.SGD","LU0345775950.USD","LU2488822045.USD","BK1502","LU0314109678.HKD","LU0197773160.USD","HK0000320264.USD","LU3063872942.SGD","LU0516422952.EUR","IE00B3M56506.USD","IE00B543WZ88.USD","LU0396098781.USD","LU1044876610.USD","LU0128522157.USD","LU2097828474.EUR","LU0320764243.SGD","LU0819121731.USD","LU0588545490.SGD","SG9999001051.SGD","LU0572939691.SGD","89988","LU0054450605.USD","LU1720051017.SGD","SG9999001226.SGD","LU0648948544.HKD","LU1051769294.HKD","LU0320764755.SGD","LU0359201885.HKD","BK1501","LU0700851271.USD","LU1242518931.SGD","LU0163747925.USD","LU0130518102.USD","BK1615","LU1831875114.USD"],"gpt_icon":1},{"id":"2607080136","title":"上海医药：关于公司控股股东及一致行动人的增持计划，目前正在有序实施中","url":"https://stock-news.laohu8.com/highlight/detail?id=2607080136","media":"证券日报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607080136?lang=zh_cn&edition=full","pubTime":"2026-01-29 21:19","pubTimestamp":1769692760,"startTime":"0","endTime":"0","summary":"证券日报网讯1月29日，上海医药在互动平台回答投资者提问时表示，关于公司控股股东及一致行动人的增持计划，目前正在有序实施中。公司始终严格遵守信息披露的相关法律法规及监管要求，若增持进展达到规定的披露标准，公司将及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601293635588171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0097","BK0209","BK0028","BK0020","BK0099","BK0183","BK0187","BK1197","02607","601607","BK0175","BK0196","BK0188","BK0012","BK0184"],"gpt_icon":0},{"id":"2607870796","title":"上海医药(02607)：七味防己黄芪颗粒获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2607870796","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607870796?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:37","pubTimestamp":1769679444,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，近日，上海医药集团股份有限公司下属正大青春宝药业有限公司研发的“七味防己黄芪颗粒” 收到国家药品监督管理局核准签发的《药物临床试验批准通知书》。七味防己黄芪颗粒为公司研发的中药1.1类创新药，截至本公告披露日，该产品尚未在国内外上市。本次七味防己黄芪颗粒获得临床试验批准通知书，对公司经营情况无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0099","BK0183","BK0196","BK0187","BK0175","BK0097","BK0209","BK0028","02607","601607","BK0012","BK0184","BK0020","BK1197"],"gpt_icon":0},{"id":"2606234565","title":"每周股票复盘：上海医药（601607）B023细胞注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2606234565","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606234565?lang=zh_cn&edition=full","pubTime":"2026-01-25 01:30","pubTimestamp":1769275832,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，上海医药报收于17.48元，较上周的17.36元上涨0.69%。本周关注点公司公告汇总：B023细胞注射液获临床试验批准，为I类创新型生物制品。公司公告汇总上海医药集团股份有限公司下属上药生物治疗自主研发的B023细胞注射液收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意开展针对不可手术的经标准治疗失败的、无有效治疗方式的局部晚期或转移性实体瘤的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0097","601607","BK0099","BK0196","BK0184","02607","BK0012","BK0175","BK0020","BK0028","BK1197","BK0187","BK0183","BK0209"],"gpt_icon":0},{"id":"2605131422","title":"上海医药最新公告：马来酸阿伐曲泊帕片获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2605131422","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605131422?lang=zh_cn&edition=full","pubTime":"2026-01-23 15:47","pubTimestamp":1769154461,"startTime":"0","endTime":"0","summary":"上海医药(601607.SH)公告称，公司下属上海上药信谊药厂有限公司的马来酸阿伐曲泊帕片收到国家药品监督管理局颁发的《药品注册证书》，该药品获得批准生产。该药品适用于慢性肝病相关血小板减少症的成年患者以及既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症（ITP）成人患者。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300020092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0012","BK0196","BK0209","BK0184","601607","BK0175","BK0028","02607","BK0188","BK1197","BK0020","BK0099","BK0183","BK0097"],"gpt_icon":0},{"id":"2605422372","title":"上海医药：普瑞巴林胶囊获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2605422372","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605422372?lang=zh_cn&edition=full","pubTime":"2026-01-23 15:37","pubTimestamp":1769153830,"startTime":"0","endTime":"0","summary":"【上海医药：普瑞巴林胶囊获得药品注册证书】上海医药公告，公司全资子公司常州制药厂有限公司收到新加坡食品药品监督管理局（HSA）签发的普瑞巴林胶囊《药品注册证书》。该产品用于治疗带状疱疹后神经痛、糖尿病外周神经痛、纤维肌痛和脊髓损伤引起的神经性疼痛以及癫痫的辅助治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601233628827261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","BK0187","BK0196","BK0209","BK0097","BK0183","601607","BK0188","02607","BK0012","BK1197","BK0099","BK0175","BK0184","BK0020"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774027814603,"stockEarnings":[{"period":"1week","weight":-0.0231},{"period":"1month","weight":-0.0157},{"period":"3month","weight":-0.0568},{"period":"6month","weight":-0.0516},{"period":"1year","weight":-0.1021},{"period":"ytd","weight":-0.0479}],"compareEarnings":[{"period":"1week","weight":-0.0338},{"period":"1month","weight":-0.0306},{"period":"3month","weight":0.0171},{"period":"6month","weight":0.0359},{"period":"1year","weight":0.1608},{"period":"ytd","weight":-0.003}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"0人","perCapita":"--","listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","registeredCapital":"370836万元","survey":" 上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是硫酸羟氯喹片、多糖铁复合物胶囊、注射用乌司他丁、胃复春胶囊、双歧杆菌三联活菌制剂。报告期内，公司再度入选《财富》世界500强和全球最具价值医药品牌榜25强，排名分别提升至第407位和第19位。","listedPrice":4.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}